Volume 23, Issue 7 (July 2025)                   IJRM 2025, 23(7): 587-589 | Back to browse issues page

Ethics code: IR.ARUMS.REC.1399.604

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Salehzadeh F, Mohammadi Kebar Y, Nezhadseifi E. Familial Mediterranean fever and reproductive systems, our experience in two decades: A letter to editor. IJRM 2025; 23 (7) :587-589
URL: http://ijrm.ir/article-1-3483-en.html
Familial Mediterranean fever and reproductive systems, our experience in two decades: A letter to editor
Farhad Salehzadeh1 , Yousef Mohammadi Kebar *2 , Elham Nezhadseifi3
1- Pediatric Department, Bouali Children's Hospital, Ardabil University of Medical Sciences (ARUMS), Ardabil, Iran.
2- Emam Khomeini Hospital, Ardabil University of Medical Sciences, Ardabil, Iran. , yousefmk506@yahoo.com
3- Emam Khomeini Hospital, Ardabil University of Medical Sciences, Ardabil, Iran.
Abstract:   (697 Views)
Due to the chronic nature of familial Mediterranean fever (FMF), there have always been conflicting reports regarding the effect of disease complications such as amyloidosis and its treatment by colchicine on the reproductive system, fertility, and pregnancy (1). The presence of recurring peritonitis and its possibility of intestinal obstruction has led to a secondary effect on the reproductive system and increased risk of infertility and miscarriage. Continuation of colchicine with its potential teratogenic and birth defects, and even premature delivery with the possibility of early miscarriage in case of attacks, are the main challenges in females with FMF. The presumptive side effects of treatment, such as oligospermia and azoospermia, have been a dilemma for males with FMF. Finally, following pregnancy, breastfeeding by the infant, in case of colchicine consumption by the mother, is another issue that needs to be discussed more (1). Here we discuss FMF and its effect on reproductive systems of women, and we share our 2 decades of experience considering this complicated issue. This study included all women with FMF at Bouali Children’s hospital, Ardabil and the FMF Registration Center in Iran (http://WWW.FMFIRAN.IR). Nearly 600 patients were enrolled in this study; all patients had FMF according to Tel-Hashomer clinical criteria and/or based on MEFV gene mutation analysis. In 2 decades, 11 female patients with FMF, phenotypically and or genetically confirmed, without renal or amyloidosis-related complications of FMF, decided to become pregnant. All of them were advised to continue taking colchicine (1–2 mg daily) throughout their pregnancy and lactation periods; any dose reduction of colchicine was not suggested. All were in their active reproductive age of life, and most were primipara. 3 women showed M694V mutations as homozygotes, one woman had M680I homozygotes, and 5 women had compound heterozygotes, and the rest were heterozygote mutations.
Full-Text [PDF 360 kb]   (659 Downloads) |   |   Full-Text (HTML)  (157 Views)  
Type of Study: Letter to Editor | Subject: Reproductive Epidemiology
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Designed & Developed by : Yektaweb